Patent 7108990 was granted and assigned to ChemoCentryx on September, 2006 by the United States Patent and Trademark Office.
The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.